logo

Invivo Therapeutics Holdings Corp. (NVIV)



Trade NVIV now with
  Date
  Headline
11/22/2019 4:39:33 PM InVivo Therapeutics Announces Closing Of Public Offering Of Common Stock
11/21/2019 8:08:10 AM InVivo Therapeutics Announces Pricing Of Public Offering Of 7 Mln Shares At $0.12/shr
10/22/2019 8:11:47 AM InVivo Therapeutics Provides Enrollment Update For INSPIRE 2.0 Study For Acute Spinal Cord Injury
7/12/2019 8:04:28 AM InVivo Therapeutics Postpones 2019 Annual Meeting Of Stockholders
6/14/2019 8:06:34 AM InVivo Therapeutics Reports Adjournment Of Annual Meeting
1/14/2019 8:14:42 AM InVivo Therapeutics Names Richard Christopher CFO And Treasurer, Effective Jan.14
10/2/2018 8:05:40 AM InVivo Therapeutics Enters Joint Research Agreement With Q Therapeutics
6/25/2018 4:07:50 PM InVivo Therapeutics Announces Closing Of $15.2 Mln Public Offering
6/21/2018 9:05:36 AM InVivo Therapeutics Prices Public Offering Of 388,403 Shares Of Its Common Stock
5/2/2018 8:07:42 AM InVivo Announces Presentation Of Complete Six-Month Primary Endpoint Results From INSPIRE Study
3/19/2018 8:11:39 AM InVivo Therapeutics Announces Top-line Findings From Its CONTEMPO Registry Study
3/12/2018 8:18:36 AM InVivo Therapeutics FY Net Loss Of $26.75 Mln Or $0.81/shr Vs. Net Loss Of $23.44 Mln Or $0.76/shr Last Year
3/8/2018 8:12:19 AM InVivo Therapeutics Receives FDA Approval For Pivotal, Randomized, Controlled Trial Of Neuro-Spinal Scaffold
2/5/2018 8:09:53 AM InVivo Therapeutics Appoints Richard Toselli As President And CEO
  
 
>